Saskatchewan Adopts Rapid HIV Viral Load Testing in Labour Wards to Protect Newborns

Key facts

Under the newly expanded program, healthcare facilities across Saskatchewan are integrating rapid nucleic acid diagnostic platforms directly into maternity wards. When a patient with HIV—or an individual presenting in labour whose viral status is unknown or unverified—arrives to give birth, clinical staff can draw blood and run an on-site test that quantifies the circulating viral copies per millilitre of plasma in roughly one to two hours.

This immediate diagnostic turnaround replaces a workflow that historically depended on central reference laboratories. In standard hospital operations, blood samples drawn from labouring mothers had to be batched and transported to specialized virology facilities, such as the Roy Romanow Provincial Laboratory in Regina or university medical centres in Saskatoon. Because processing and reporting back to the clinical floor often took anywhere from one day to nearly a week, obstetricians and pediatricians frequently had to make urgent decisions about neonatal drug regimens without knowing the mother's exact viral load at the moment of delivery.

Under clinical protocols established for perinatal care, the viral load of the mother at delivery is the single most critical factor in predicting the risk of vertical transmission—the transmission of the virus from mother to child in utero, during labour, or through breast milk. If a mother has maintained an undetectable viral load through antiretroviral therapy, the likelihood of transmission is near zero, and the newborn requires minimal, low-toxicity preventive medication. If the viral load is elevated, the baby faces substantial transmission risk and requires an immediate multi-drug course of antiretrovirals initiated within the first 6 to 12 hours of life. By providing precise viral load metrics within the delivery window, the on-site program allows maternity teams to select the exact pharmacological regimen needed before the optimal therapeutic window closes.

Why it matters

The introduction of widespread point-of-care viral load testing in delivery rooms represents an important shift in perinatal HIV prevention, carrying direct clinical consequences for mothers and infants. In pediatric medicine, the first hours following delivery represent an irreplaceable window for post-exposure prophylaxis. When maternal viral load is high, administering a combination of three antiretroviral drugs to the infant as soon as possible after birth can halt viral replication before a systemic infection becomes permanent. Conversely, subjecting an infant to combination therapy when the mother is already virologically suppressed exposes the newborn to unnecessary drug toxicity and side effects, including gastrointestinal distress and bone marrow suppression.

Beyond immediate pharmacological choices, real-time viral load results govern post-delivery infant feeding guidelines. Major pediatric and infectious disease bodies, including the Canadian Paediatric Society and international agencies, have traditionally advised formula feeding for infants born to mothers living with HIV in high-resource settings to eliminate postnatal transmission. However, evolving clinical guidance increasingly recognizes that mothers with sustained, confirmed viral suppression who receive ongoing clinical support may choose to breastfeed with minimal risk. Having immediate confirmation of a suppressed viral load at delivery allows medical teams and mothers to have informed, evidence-based discussions about feeding choices and ongoing infant testing schedules, mitigating trauma and reducing historical stigma associated with maternal HIV care.

Saskatchewan has occupied a unique and challenging position within Canada's public health landscape regarding HIV for more than fifteen years. In 2010, the province declared an HIV strategy after public health surveillance revealed infection rates surging to more than double and triple the Canadian national average. According to surveillance data published by the Public Health Agency of Canada and the Saskatchewan Ministry of Health, the province has repeatedly recorded incidence rates exceeding 15 to 20 cases per 100,000 population, whereas the national Canadian average has generally hovered around 5 to 6 cases per 100,000.

Unlike many other regions in North America and Western Europe, where the primary driver of transmission has historically been sexual contact among men who have sex with men, the epidemic in Saskatchewan has been heavily driven by injection drug use and deeply intertwined with systemic socioeconomic factors. A substantial portion of diagnoses in the province occurs among individuals facing severe housing instability, poverty, rural isolation, and intergenerational trauma, disproportionately affecting Indigenous communities. In this epidemiological context, pregnant individuals frequently encounter substantial barriers to consistent prenatal care, including geographic distance from specialized tertiary clinics, lack of transportation, fear of child welfare apprehension, and healthcare discrimination.

As a consequence, patients in Saskatchewan have been more likely to arrive at hospital in active labour with incomplete prenatal records, intermittent adherence to antiretroviral treatment, or completely undiagnosed infections. While point-of-care rapid antibody tests have existed for years to provide a binary positive-or-negative screening result in minutes, antibody tests cannot indicate whether an individual on medication has an active, suppressed, or surging viral load. Determining the actual quantity of viral RNA has traditionally required automated polymerase chain reaction instruments confined to Level 3 or highly certified hospital laboratories. Recent technological advancements in cartridge-based point-of-care testing systems—originally scaled during global tuberculosis, HIV in sub-Saharan Africa, and respiratory virus programs—have finally made it possible to conduct true quantitative viral load analysis at the hospital bedside without specialized laboratory staff.

Reaction

While formal public statements from provincial health authorities have not been widely publicized, clinical stakeholders, public health advocates, and patients have historically pushed for low-barrier diagnostic tools in birthing units. According to reporting by Maeve Ellis, mothers with lived experience in Regina have expressed optimism that on-site testing will spare future families the profound anxiety and uncertainty that accompanied prior delivery experiences under delayed testing regimes.

Professional healthcare associations, including the Society of Obstetricians and Gynaecologists of Canada and regional pediatric infectious disease working groups, are expected to monitor the operational data emerging from Saskatchewan's rollout. In similar medical transitions, clinical staff typically welcome technologies that resolve emergency diagnostic ambiguities during night shifts and weekends, when hospital laboratory staffing is often reduced. However, health economists and hospital administrators are also expected to evaluate the ongoing costs of single-use testing cartridges and device maintenance against the cost savings achieved through avoided neonatal admissions and optimized drug utilization.

What we don't know yet

Several practical and operational details surrounding the deployment remain unverified in the currently available reporting. First, it is not yet clear which specific hospitals have received the devices—whether the equipment is restricted to major urban centres such as Regina General Hospital and Jim Pattison Children's Hospital in Saskatoon, or whether units have also been distributed to regional and northern health facilities in Prince Albert, North Battleford, and La Ronge where transport times to provincial laboratories are longest. Second, the exact device manufacturer and the specific technological platform deployed were not identified in the initial reporting by Maeve Ellis, leaving questions regarding the diagnostic test's precise analytical sensitivity, limit of detection, and failure rate in active clinical environments. Finally, it remains unstated whether provincial health authorities have established updated, standardized clinical guidelines across the Saskatchewan Health Authority to dictate mandatory neonatology consultation based specifically on these point-of-care numerical cutoffs.

What to watch

Over the coming months, public health observers and clinical researchers will watch for several key indicators to assess the success and potential national expansion of the Saskatchewan initiative. The first benchmark will be the presentation of clinical outcome data at upcoming national medical forums, such as the annual Canadian Conference on HIV/AIDS Research or meetings of the Canadian Paediatric Society, detailing how many deliveries utilized the rapid testing and whether any vertical transmissions occurred. Healthcare analysts will also monitor whether other Canadian provinces with elevated rates of maternal HIV or rural populations, including Manitoba, Alberta, and parts of the northern territories, initiate pilot projects of their own based on Saskatchewan's operational protocols. Additionally, future administrative reviews will reveal how the diagnostic workflow impacts the length of hospital stays for newborns and whether testing results correlate smoothly with confirmation testing performed concurrently by centralized provincial laboratories.

This report is based on original news reporting by Maeve Ellis.